STAAR Surgical Company provided sales guidance for the first quarter ended March 29, 2024. For the period, the company expects Net sales to be in excess of $77 million with U.S. ICL sales expected to be $5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.96 USD | -3.10% | -4.63% | +47.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.26% | 2.28B | |
-3.72% | 186B | |
-2.60% | 107B | |
-3.79% | 67.44B | |
+2.66% | 50.03B | |
+16.39% | 47.81B | |
+4.79% | 41.03B | |
+1.38% | 26.85B | |
+1.52% | 25.82B | |
-1.17% | 25.01B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024